Journal
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
Volume 296, Issue 3, Pages E415-E421Publisher
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajpendo.90887.2008
Keywords
-
Categories
Funding
- The Canadian Institute of Health Research
- Meredith and Malcolm Silver Cardiovascular Award
Ask authors/readers for more resources
Ali S, Drucker DJ. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab 296: E415-E421, 2009. First published December 30, 2008; doi:10.1152/ajpendo.90887.2008.-Glucagon is secreted from the alpha-cells of the pancreatic islets and regulates glucose homeostasis through modulation of hepatic glucose production. As elevated glucagon levels contribute to the pathophysiology of hyperglycemia in subjects with type 2 diabetes, reduction of glucagon receptor gene (Gcgr) activity represents a potential target for the treatment of T2DM. Herein, we review current concepts of glucagon action in hepatic and extrahepatic tissues and evaluate the therapeutic potential, mechanisms of action, and safety of reducing Gcgr signaling for the treatment of T2DM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available